| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Redx Pharma starts dosing patients in cancer treatment trial
StockMarketWire.com
|
Cancer and fibrosis focused Redx Pharma said it had initiated dosing of the first patient cohort in a trail involving its lead drug candidate.
The company's drug, RXC004, was being administered in combination with nivolumab.
RXC004 was also currently being evaluated as a monotherapy, from which top line results were expected by mid 2021.
At 9:32am: (LON:REDX) Redx Pharma Plc share price was 0p at 62.5p
Story provided by StockMarketWire.com
|
|
|
|
|
|
